PTX 2.44% 4.2¢ prescient therapeutics limited

Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-303

  1. 1,656 Posts.
    lightbulb Created with Sketch. 198
    Correct jpg...,
    The ORR, including the clinical passing ( R.I.P), was at 100% not unlike the 1b study.
    Also of ‘special’ interest, not sure if it is a precedent result or not, is the durability on partial response (PR) according to announcement.

    If you do purchase the article, and are willing to share the 2 year regression figures, would appreciate it in advance.


 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.